IMS Health's top 10 'harbingers of change' in pharmaceutical business

Article

Payer trends dominate near-term outlook

The IMS Health Institute for Healthcare Informatics has published a white paper, “Harbingers of Change in Healthcare: Implications for the role and use of medicines,” that’s worth a look. It is a little sketchy on how the 10 items were chosen (the report lists five IMS Health analysts as authors; and that’s it), while noting that the list is “not intended to be exhaustive.” On the other hand, the items are backed up by up-to-date market data (IMS Health’s core service); for example, it notes that Medicare prescriptions for sofosburvir (Gilead Science’s Sovaldi) and simeprivir (J&J’s Olysio), for hepatitis C, jumped eightfold (to over 105,000 prescriptions by September (the first 39 weeks the drugs were on the market), as compared to the introduction of earlier, interferon-based treatments introduced in 2011. That’s a solid indicator of the extent to which prescribers were “warehousing” patients in anticipation of the drugs’ approvals.

Here are the 10:

  • Technology Rushes to Healthcare: Google, Apple and Samsung make new overtures to bring mobile, cloud and wearable technology to healthcare
  • Hepatitis C Cluster of Innovation Triggers New Thinking on Financing of Cures: Cures can save billions in the long term but have high upfront costs
  • Breakthrough Vaccines Become Available: Philanthropy-driven research begins to deliver life-saving vaccines for communicable diseases
  • Biologics Reach Patients in Pharmerging Countries: Patient access to biologic medicines in pharmerging countries is growing rapidly
  • Governments Unshackle Data: Wide release of granular healthcare data adds new data transparency and accountability
  • Medicine Spending Growth Returns to Developed Countries: A return to higher growth in drug spending after years of lower growth will create new challenges
  • US Payment and Delivery Models Shift Focus to Value: Accountable Care Organizations (ACOs) are forming faster than anticipated and will remake the U.S. healthcare environment
  • Clinicians Consider Costs: Doctors are being encouraged to weigh the cost of treatments with their benefits
  • China Loosens Price Caps: Sustaining the availability and quality of essential drugs may mean higher generic prices
  • Purchasing Groups Consolidate Across a Fragmented Landscape: Mega trans-Atlantic purchasing groups rebalance negotiating power for generic drugs

Arguably, several of these harbingers are already established fact: clinicians’ cost focus is well along (often through formulary requirements); and ACOs have been forming up for a couple years now (ACOs and “ACO-like” organizations now cover 10% of the US population). But 10 trends’ near- and long-term effects are seeping into more and more of how the pharma industry will address its clientele, from prescribers to central governments worldwide.

The report is available here.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.